绿帽献妻

Adres sorunlar谋n谋 a艧mak i莽in en g眉ncel ba臒lant谋 olan her zaman 枚nem ta艧谋yor.

Kullan谋c谋lar, g眉venli eri艧im sa臒lamak i莽in sayfas谋n谋 tercih ediyor.

Promosyonlardan yararlanmak isteyenler sayfas谋n谋 s谋k s谋k ziyaret ediyor.

Dijital e臒lenceyi art谋rmak i莽in kategorileri ilgi 莽ekiyor.

Tenis ve voleybol gibi farkl谋 spor dallar谋nda f谋rsatlar谋 bulunuyor.

Kazanc谋n谋 art谋rmak isteyenler i莽in promosyonlar谋 cazip hale geliyor.

Ma莽 sonu raporumu yazarken sonu莽 k谋sm谋n谋n ortas谋nda verilerini an谋p kilit farklar谋枚zetledim.

Her an eri艧im isteyen oyuncular i莽in uygulamas谋 tasarland谋.

Kumarhane heyecan谋n谋 arayanlar i莽in kategorisi vazge莽ilmezdir.

Dijital oyun deneyimini art谋rmak i莽in platformlar谋 kullan谋l谋yor.

Mobilde h谋zl谋 karar vermek i莽in metnin orta sat谋r谋na k谋sayolunu ekledim.

2025 y谋l谋 i莽in planlanan yenilikleri bahis莽ileri heyecanland谋r谋yor.

Tenis turnuvalar谋na bahis oynamak isteyenler ba臒lant谋s谋na t谋kl谋yor.

Ak谋ll谋 telefon kullan谋c谋lar谋 ile daha h谋zl谋 i艧lem yapabiliyor.

Futbol derbilerine 枚zel y眉ksek oranlar k谋sm谋nda bulunuyor.

Modern altyap谋s谋yla kullan谋c谋 deneyimini geli艧tirmeyi hedefliyor.

T眉rkiye鈥檇e ad谋n谋 duyuran g眉venilir yap谋s谋yla fark yarat谋yor.

Kumarhane keyfi ya艧amak i莽in tercih ediliyor.

Oyuncular kolay giri艧 i莽in sayfas谋n谋 kullan谋yor.

Her oyuncu kolay eri艧im i莽in adresini ziyaret ediyor.

Kay谋tl谋 oyuncular kolayca oturum a莽mak i莽in ba臒lant谋s谋n谋 kullan谋yor.

Oyuncular h谋zl谋 eri艧im i莽in ba臒lant谋s谋na y枚neliyor.

Adres de臒i艧ikliklerinden haberdar olmak i莽in d眉zenli kontrol edilmeli.

Bahis sekt枚r眉ndeki yenilik莽i yakla艧谋m谋yla bilinen s眉rekli geli艧iyor.

Bahis d眉nyas谋nda deneyim ve yenili臒i bir arada sunan fark谋n谋 kan谋tl谋yor.

Futbol derbilerine bahis yapmak isteyenler sayfas谋n谋 ziyaret ediyor.

Mobil kullan谋c谋 deneyimini geli艧tiren sistemi olduk莽a pop眉ler.

Klasik kumarhane heyecan谋n谋 evinize getiren platformda bolca mevcut.

Futbol ve basketbol kuponlar谋 yapmak i莽in kategorisi tercih ediliyor.

2025鈥檛e kullan谋c谋 dostu tasar谋m谋yla s眉r眉m眉 geliyor.

Her oyuncunun g眉venli臒ini sa臒layan anlay谋艧谋 sekt枚rde yay谋l谋yor.

Rulet, blackjack ve slot makineleriyle dolu b眉y眉k ilgi g枚r眉yor.

T眉rkiye鈥檇e kad谋n oyuncular谋n oran谋 h谋zla artmakta ve kad谋n kullan谋c谋 dostu bir platform geli艧tirmektedir.

Curacao Gaming Authority, y谋ll谋k lisans yenilemelerini s谋k谋 denetler ve her y谋l bu s眉reci ba艧ar谋yla tamamlar.

T眉rkiye鈥檇eki bahis tutkunlar谋 i莽in yenilik莽i 莽枚z眉mler sunmaya devam ediyor.

Lisansl谋 yap谋s谋 ile g眉ven veren kullan谋c谋lar谋n tercihi oluyor.

Online e臒lencenin artmas谋yla birlikte kategorileri daha pop眉ler oluyor.

Her rulet turu ger莽ek zamanl谋 olarak ba艧lar ve gecikmesiz yay谋n teknolojisiyle kesintisiz 莽al谋艧谋r.

陌nternet 眉zerinden daha kolay eri艧im i莽in sayfas谋 kullan谋l谋yor.

T眉rkiye鈥檇e slot kategorisinde en y眉ksek kazan莽 rekoru milyon TL seviyesine ula艧m谋艧t谋r, b眉y眉k 枚d眉ller sunar.

Drug maker unveils oral treatment to lessen risk of COVID-19 hospitalisations, deaths

绿帽献妻 October 3, 2021 Activations

Photo: BoomLive.In

*Drug manufacturer Merck notes drug Molnupiravir reduces the risk of hospitalisations or deaths from the Coronavirus by approximately 50 percent, as it plans for worldwide distribution, if granted approval by the regulatory authority

Gbenga Kayode | 绿帽献妻

Sequel to the company鈥檚 disappointing clinical trial results with two COVID-19 Vaccines earlier this year, drug manufacturer Merck is returning to the table with an oral treatment against the damaging pandemic.

绿帽献妻 learnt the drug maker鈥檚 year-long clinical study involving the oral antiviral medicine Molnupiravir, a drug originally developed for the treatment of influenza, found that the drug reduced the risk of hospitalisation or death from the Coronavirus by approximately 50 percent.

With those results, Merck says it plans to seek Emergency Use Authorisation (EUA) in the United States (US), agency report said.

Oral antiviral medicine Molnupiravir聽聽Photo:聽

Certain Merck Spokesperson was quoted to have said that Molnupiravir鈥檚 potential could be game-changing.

鈥淣ot only is it effective against COVID-19, but other coronavirus strains, as well,鈥� they said.

Merck reported no deaths among those who received Molnupiravir in its outpatient study. That compared to 8 deaths in patients who received a placebo, report stated.

Robert M. Davis, Chief Executive Officer and President of Merck, also said: 鈥淢ore tools and treatments are urgently needed to fight the COVID-19 pandemic, which has become a leading cause of death and continues to profoundly affect patients, families, and societies and strain health care systems all around the world.

鈥淲ith these compelling results, we are optimistic that molnupiravir can become an important medicine as part of the global effort to fight the pandemic.鈥�

A plan for global distribution

It was learnt if granted approval, Merck says it is prepared to produce 10million courses of treatment by the end of 2021, with more doses expected to be produced in 2022.

Merck’s plans for Molnupiravir are global. In fact, the Phase 3 portion of the trial was conducted in more than 170 planned sites in countries, including Argentina, Brazil, Canada, Chile, Colombia, Egypt, France, Germany, Guatemala, Israel, Italy, Japan, Mexico, Philippines, Poland, Russia, South Africa, Spain, Sweden, Taiwan, Ukraine, the United Kingdom, and the United States.

Report also indicates the drug company has already submitted marketing applications to other global drug regulators and stated that it plans to implement a tiered pricing approach if it is authorised or approved.

The pricing system will reflect countries鈥� relative ability to finance their health response to the pandemic, Merck said.

Kindly share this story

绿帽献妻

Drug maker unveils oral treatment to lessen risk of COVID-19 hospitalisations, deaths

Kindly Share This Story

ABOUT US

SECTIONS

SECTIONS

QUOTE

Connect With Us On:

CONTACTS: